Aduro Biotech Inc. (ADRO) Receives Buy Rating from Roth Capital
Aduro Biotech Inc. (NASDAQ:ADRO)‘s stock had its “buy” rating restated by stock analysts at Roth Capital in a research note issued to investors on Friday. They presently have a $20.00 target price on the stock. Roth Capital’s price target would suggest a potential upside of 43.37% from the stock’s previous close.
Other analysts have also issued research reports about the stock. Canaccord Genuity set a $30.00 price target on shares of Aduro Biotech and gave the company a “buy” rating in a research note on Monday, October 24th. Leerink Swann set a $14.00 target price on shares of Aduro Biotech and gave the stock a “buy” rating in a research note on Monday, October 24th. Finally, FBR & Co reiterated a “buy” rating on shares of Aduro Biotech in a research note on Tuesday, November 22nd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $19.60.
Shares of Aduro Biotech (NASDAQ:ADRO) opened at 13.95 on Friday. The firm’s market cap is $937.19 million. Aduro Biotech has a 1-year low of $7.26 and a 1-year high of $34.95. The stock’s 50 day moving average is $12.58 and its 200-day moving average is $12.94.
Aduro Biotech (NASDAQ:ADRO) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.09. The business had revenue of $3.79 million for the quarter, compared to the consensus estimate of $3.99 million. Aduro Biotech had a negative net margin of 72.04% and a negative return on equity of 23.45%. The business’s revenue for the quarter was down 79.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.01 EPS. Analysts expect that Aduro Biotech will post ($1.34) earnings per share for the current year.
In related news, CEO Stephen T. Isaacs sold 27,273 shares of the business’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $12.67, for a total value of $345,548.91. Following the transaction, the chief executive officer now directly owns 129,473 shares of the company’s stock, valued at approximately $1,640,422.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Thomas W. Dubensky sold 25,000 shares of the business’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $14.03, for a total transaction of $350,750.00. Following the completion of the transaction, the insider now directly owns 16,407 shares in the company, valued at $230,190.21. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of the company. Acrospire Investment Management LLC increased its position in shares of Aduro Biotech by 27.6% in the second quarter. Acrospire Investment Management LLC now owns 9,700 shares of the company’s stock worth $110,000 after buying an additional 2,100 shares during the period. BlackRock Group LTD increased its stake in Aduro Biotech by 108.1% in the third quarter. BlackRock Group LTD now owns 11,031 shares of the company’s stock valued at $136,000 after buying an additional 5,729 shares during the period. Wells Fargo & Company MN increased its stake in Aduro Biotech by 1.1% in the third quarter. Wells Fargo & Company MN now owns 12,258 shares of the company’s stock valued at $152,000 after buying an additional 139 shares during the period. BlackRock Inc. increased its stake in Aduro Biotech by 1,850.5% in the second quarter. BlackRock Inc. now owns 12,600 shares of the company’s stock valued at $142,000 after buying an additional 11,954 shares during the period. Finally, Parametric Portfolio Associates LLC acquired a new stake in Aduro Biotech during the second quarter valued at approximately $143,000. 28.50% of the stock is currently owned by institutional investors.
Aduro Biotech Company Profile
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.